Mast cell tumors are among the most common canine skin tumors, with welfare outcomes varying enormously depending on grade and completeness of treatment.
Mast cell tumor welfare management requires attention to both the tumor itself and the systemic effects of mast cell mediator release. Manipulation of MCT during physical examination or biopsy can trigger histamine release causing local swelling and redness, and in severe cases, anaphylactic reactions. Pre-treatment with antihistamines and proton pump inhibitors before surgery reduces this risk. The welfare of dogs with high-grade MCT requires honest oncological assessment: some dogs achieve long remissions with surgery and targeted therapy; others have rapidly progressive disease. Clear welfare benchmarks established at diagnosis - what quality of life looks like, when to transition to palliative care - prevent unnecessary suffering during failed treatment and enable timely end-of-life decisions.